#None #Target RWE #MASH #EGIDs #Durham, N.C.

Key Findings from ACG 2024 Presented by Target RWE

On November 26, 2024, at the American College of Gastroenterology (ACG) Annual Meeting, Target RWE, an authority in real-world evidence solutions focusing on liver disease and gastroenterology, unveiled significant research findings derived from its patient cohorts suffering from metabolic dysfunction-associated steatohepatitis (MASH) and eosinophilic gastrointestinal diseases (EGIDs). These insights are pivotal in enhancing the understanding of disease characteristics, population demographics, and treatment methodologies for patients with these conditions.

Comprehensive Registries for Liver Disease and Gastroenterology

Target RWE operates robust observational studies, notably TARGET-LD for liver disease and TARGET-GASTRO for gastroenterology. With the inclusion of over 600,000 patients in TARGET-LD and around 30,000 in TARGET-GASTRO, the organization successfully captures intricate patient journeys through complex disease landscapes, notably metabolic disorders as seen in TARGET-METABOLIC. This extensive data set allows Target RWE to generate meaningful real-world insights, essential for informing clinical research and enhancing therapy approaches.

Key Findings on Treatment Efficacy

Application of SGLT2 and DPP4 Inhibitors

One of the highlighted studies from TARGET-NASH focused on the impact of sodium-glucose transport protein 2 (SGLT2) and dipeptidyl peptidase 4 (DPP4) inhibitors on patients suffering from metabolic dysfunction-associated steatotic liver disease (MASLD). The results indicated a correlation between the usage of these medications and reduced all-cause mortality compared to those who did not use them. Importantly, the study also reported that patients benefiting from these treatments were more frequently enrolled in academic institutions, illustrating possible differences in treatment accessibility and management. Dr. A. Sidney Barritt IV, an esteemed professor of medicine and hepatology director at the University of North Carolina, emphasized the significance of these findings, highlighting the intersectionality of metabolic syndrome and liver disease as a substantial clinical opportunity deserving further exploration.

Medication Access for Eosinophilic Esophagitis Patients

Another critical analysis presented was related to the TARGET-EGIDs cohort, revealing that nearly 10% of newly diagnosed eosinophilic esophagitis (EoE) patients did not receive any form of pharmacologic treatment post-diagnosis. The research found older patients and those without specific EoE symptoms or complications were less likely to be prescribed medication. Dr. Evan S. Dellon, a notable figure in the field from the University of North Carolina, remarked on how this data unveils complexities within EoE treatment patterns, particularly emphasizing the disparities in treatment among different patient demographics.

Importance of Observational Studies

The insights from Target RWE's TARGET-LD and TARGET-GASTRO studies are immensely beneficial for a comprehensive understanding of the interrelated patient experiences between liver disease and gastroenterology. These findings are crucial to informing clinical practices, optimizing treatment strategies, and supporting the development of pioneering therapeutic interventions aimed at enhancing patient care across these interconnected disciplines.

For more information regarding Target RWE’s extensive longitudinal studies and patient cohorts, visit their official website or contact them directly to learn more about their groundbreaking work in generating real-world evidence.

• ---

For further details, visit Target RWE.